Journal
CANCER MEDICINE
Volume 12, Issue 10, Pages 11073-11096Publisher
WILEY
DOI: 10.1002/cam4.5594
Keywords
chemoresistance; colorectal cancer; novel strategies; reversal of resistance
Categories
Ask authors/readers for more resources
Colorectal cancer is a common gastrointestinal malignancy with high morbidity and fatality. Chemotherapy is effective in treating CRC, but chemoresistance limits its efficacy. Strategies such as drug repurposing, gene therapy, protein inhibitors, natural herbal compounds, new drug delivery systems, and combination therapy are being investigated to overcome chemoresistance.
Colorectal cancer (CRC) is a common gastrointestinal malignancy with high morbidity and fatality. Chemotherapy, as traditional therapy for CRC, has exerted well antitumor effect and greatly improved the survival of CRC patients. Nevertheless, chemoresistance is one of the major problems during chemotherapy for CRC and significantly limits the efficacy of the treatment and influences the prognosis of patients. To overcome chemoresistance in CRC, many strategies are being investigated. Here, we review the common and novel measures to combat the resistance, including drug repurposing (nonsteroidal anti-inflammatory drugs, metformin, dichloroacetate, enalapril, ivermectin, bazedoxifene, melatonin, and S-adenosylmethionine), gene therapy (ribozymes, RNAi, CRISPR/Cas9, epigenetic therapy, antisense oligonucleotides, and noncoding RNAs), protein inhibitor (EFGR inhibitor, S1PR2 inhibitor, and DNA methyltransferase inhibitor), natural herbal compounds (polyphenols, terpenoids, quinones, alkaloids, and sterols), new drug delivery system (nanocarriers, liposomes, exosomes, and hydrogels), and combination therapy. These common or novel strategies for the reversal of chemoresistance promise to improve the treatment of CRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available